Detecting GPC3-Expressing Hepatocellular Carcinoma with L5 Peptide-Guided Pretargeting Approach: In Vitro and In Vivo MR Imaging Experiments

<div>L5 peptide binding assays. HepG2 cells and HL-7702 cells were incubated with either FAM (a, b) or L5-FAM (c, d), respectively, which was mounted with DAPI-containing media (e, f). Excess L5 peptide blocked the binding of HepG2 cells with L5-FAM, exemplifying competitive binding and strong affinity of L5 peptide to GPC3 (g).</div>

Contrast Media & Molecular Imaging

fig2

Figure 2

Figure 2: Detecting GPC3-Expressing Hepatocellular Carcinoma with L5 Peptide-Guided Pretargeting Approach: In Vitro and In Vivo MR Imaging Experiments 

Figure 2 | Detecting GPC3-Expressing Hepatocellular Carcinoma with L5 Peptide-Guided Pretargeting Approach: In Vitro and In Vivo MR Imaging Experiments 